China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreXgeva (denosumab) has been…
A new $100-million program aims to improve the diversity of…
Janssen is seeking to extend approval of its…
Myeloma UK is calling for more data transparency…
ALLO-715, an investigational donor-derived CAR T-cell therapy…
Administering radiation therapy to people with…